[go: up one dir, main page]

HUP1800298A1 - Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére - Google Patents

Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Info

Publication number
HUP1800298A1
HUP1800298A1 HU1800298A HUP1800298A HUP1800298A1 HU P1800298 A1 HUP1800298 A1 HU P1800298A1 HU 1800298 A HU1800298 A HU 1800298A HU P1800298 A HUP1800298 A HU P1800298A HU P1800298 A1 HUP1800298 A1 HU P1800298A1
Authority
HU
Hungary
Prior art keywords
combination
side effects
acid derivative
reduced side
beta blocker
Prior art date
Application number
HU1800298A
Other languages
English (en)
Inventor
Nagy Peter Literati
Kalman Tory
Original Assignee
N Gene Res Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Laboratories Inc filed Critical N Gene Res Laboratories Inc
Priority to HU1800298A priority Critical patent/HUP1800298A1/hu
Priority to PCT/HU2019/000033 priority patent/WO2020044067A1/en
Publication of HUP1800298A1 publication Critical patent/HUP1800298A1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU1800298A 2018-08-30 2018-08-30 Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére HUP1800298A1 (hu)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HU1800298A HUP1800298A1 (hu) 2018-08-30 2018-08-30 Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
PCT/HU2019/000033 WO2020044067A1 (en) 2018-08-30 2019-10-30 Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1800298A HUP1800298A1 (hu) 2018-08-30 2018-08-30 Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Publications (1)

Publication Number Publication Date
HUP1800298A1 true HUP1800298A1 (hu) 2020-05-28

Family

ID=89992747

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1800298A HUP1800298A1 (hu) 2018-08-30 2018-08-30 Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Country Status (2)

Country Link
HU (1) HUP1800298A1 (hu)
WO (1) WO2020044067A1 (hu)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187220A (en) 1977-08-30 1980-02-05 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US5123121A (en) 1988-03-07 1992-06-23 Bell Helmets, Inc. Helmet retention system with adjustable buckle
HU207988B (en) 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
US6458371B1 (en) 1995-12-22 2002-10-01 Medgene, Limited Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin
US6884424B2 (en) 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
HUP9701080A3 (en) 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
WO2000007580A2 (en) 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
US6887872B2 (en) 2000-03-20 2005-05-03 N-Gene Research Laboratiories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
DK1408966T3 (da) 2001-07-17 2008-06-16 N Gene Res Lab Inc Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
HUP0401177A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis
HUP0401176A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition having prpkinetic effect
HUP0500145A2 (en) 2005-01-28 2006-11-28 Gene Res Lab N Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
WO2008070010A2 (en) 2006-12-01 2008-06-12 Cytrx Corporation Hydroxylamine derivatives for the treatment of stroke
TW200901958A (en) 2007-05-04 2009-01-16 Cytrx Corp Diabetic wound healing
US20090281143A1 (en) 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
PT2484371E (pt) 2008-06-26 2015-03-03 Orphazyme Aps Uso da hsp70 como um regulador da atividade enzimática
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
ES2725893T3 (es) * 2013-03-14 2019-09-30 Andrew J S Coats Composiciones enriquecidas con S-enantiómeros de betabloqueantes para tratar la esclerosis lateral amiotrófica

Also Published As

Publication number Publication date
WO2020044067A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
IL279632B1 (en) Compounds and methods for reducing lrrk2 expression
ZA201908154B (en) Compounds and compositions for treating conditions associated with nlrp activity
SG11202103405TA (en) Compounds and compositions for treating conditions associated with nlrp activity
EP4026831A4 (en) PIPERIC ACID DERIVATIVE AND ITS APPLICATION
PL3319439T3 (pl) Kompozycja chwastobójcza zawierająca cynmetylinę i napropamid
SG11202109786UA (en) Anthelmintic aza-benzothiophene and aza-benzofuran compounds
IL288024A (en) Methods and preparations for the prevention of type 1 diabetes
SG11202010884TA (en) Dienal compound and flavor composition
PL3638277T3 (pl) Kompozycje i sposoby hamowania beta sekretazy
GB202007831D0 (en) Curtain pull
EP3575104A4 (en) CORRECTIVE TAPE THAT CAN LOCK AUTOMATICALLY AFTER MOVING A GUIDE
PL3319616T3 (pl) Kompozycje pektynowe do zapobiegania wystąpieniu i leczenia chorób zapalnych
HUP1800298A1 (hu) Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
ZA202102197B (en) Alignment of hts tapes
IL277312A (en) Combined immunotherapy with glucan cell and CD40 agonist
EP3383155A4 (en) Tape curving attachment and feeder
TWI914296B (zh) 用於治療與nlrp 活性相關的病症之化合物及組成物
IL281835A (en) Antimalarial methods and compounds
GB2594831B (en) Rheometer systems and related methods
NO20210605A1 (en) Advanced pulling prong
PL3610759T3 (pl) Element meblarski
SG11202009656UA (en) Pre-assembly of parts
AU201810756S (en) Fittings for curtains and blinds
GB2583534B (en) Curtain reel fixing assembly
HK40052424A (en) Compounds and methods for reducing lrrk2 expression

Legal Events

Date Code Title Description
FH91 Appointment of a representative
FD9A Lapse of provisional protection due to non-payment of fees